Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.
Yann-Alexandre Vano, MD, Georges-Pompidou European Hospital, Paris, France, discusses some of the exciting data being seen in the renal cell carcinoma (RCC) space.
In addition to the phase 2 BIONIKK trial (NCT02960906) which showed that treatment with nivolumab (Opdivo) in combination with ipilimumab (Yervoy) in metastatic RCC is effective, Vano highlights biomarker data from the the phase 3 CheckMate 9ER trial (NCT03141177). In this randomized, open-label study, the combination of nivolumab and cabozantinib (Cabometyx) was evaluated and compared with treatment with sunitinib (Sutent) monotherapy in patients with advanced RCC.
Here, nivolumab plus cabozantinib showed a continued clinically meaningful improvement in long-term survival and in responses among those enrolled in the study.
Vano also discusses a trial showing the efficacy of different treatments in patients with brain metastases, each of which were discussed at the 2023 Genitourinary Cancers Symposium.
Transcription:
0:10 | We have some biomarker data from CheckMate-9ER and we have updates from CheckMate-9ER [trial] of cabozantinib and nivolumab vs sunitinib [Suntent], which confirms the efficacy of this combination, but again, we have plenty of combinations in the first-line and we do not know how to use it. The biomarker parts of this trial are quite negative. We have data on the triplet of cabozantinib, nivolumab, and ipilimumab. We already know that this triplet is positive on PFS, negative on overall survival for the moment, and we know also that in lower risk patients, the triplet is not superior to the doublet. It would be a problem for this combination in the near future for the approval of this combination if these results are confirmed.
1:08 | Then, another study is showing the efficacy of different treatments in case of brain metastases. We see that brain metastasis is associated with a very poor prognosis and we have no clear efficacy of any treatments right now.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More